Prostate cancer is a common diagnosis among Australian men: roughly 200 in every 1,000 will be told they have the disease by age 85. Yet the chance of dying from it is far lower, at about 18 in 1,000 cases. That disparity is at the heart of the ongoing debate over prostate-specific antigen (PSA) testing.
The PSA test can detect cancers that might never cause symptoms or threaten a man's life. Identifying such slow-growing tumors can lead to unnecessary biopsies, treatments, and anxiety. The numbers suggest that many men diagnosed with prostate cancer will ultimately die of something else.
For men considering a PSA test, the key question is whether the benefit of early detection outweighs the risk of overdiagnosis. The Australian figures provide a concrete context for that decision, but they do not settle it—individual risk factors and preferences still matter.